Handok Pharmaceuticals, Inc.
http://www.handok.co.kr
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Handok Pharmaceuticals, Inc.
Biocon Expects US Adalimumab Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Biocon Expects US b(Humira) Market To Consolidate, Liraglutide Plans On Course
Biocon maintains it doesn’t expect the US to remain an eight to 10 player market for adalimumab biosimilars for long and also outlines expectations for its GLP-1 portfolio, led by liraglutide, seen as a major growth driver in the coming years.
Biocon Lines Up Another Liraglutide Deal, This Time In Korea
Biocon has added to its roster of liraglutide partners by striking a fresh deal in Korea with Handok for the chronic weight management treatment.
Asia Deal Watch: Ono Calls On PRISM BioLab’s Capabilities
Plus transactions involving Nissan Chemical/Sanwa Kagaku, Memel/Therabest, Chugai/Alnylam, Takeda/Kumquat, Nxera/Handok, 3SBio/CStone and deals in brief.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice